A phase 1/1b study of the tumor-activated IL-2 prodrug WTX-124 alone or in combination with pembrolizumab in patients with immunotherapy-sensitive locally advanced or metastatic solid tumors

Moser JC; Brendan Curti; See full list of authors in comments

A phase 1/1b study of the tumor-activated IL-2 prodrug WTX-124 alone or in combination with pembrolizumab in patients with immunotherapy-sensitive locally advanced or metastatic solid tumors

Moser JC, Brendan Curti, See full list of authors in comments

Research output: Other contribution

Original language	Undefined/Unknown
State	Published - Nov 1 2023

Publication series

Name	Articles, Abstracts, and Reports

Access to Document

http://digitalcommons.providence.org/publications/8362

Cite this

@misc{48d3800169a74a3f99997ebedec9e648,

title = "A phase 1/1b study of the tumor-activated IL-2 prodrug WTX-124 alone or in combination with pembrolizumab in patients with immunotherapy-sensitive locally advanced or metastatic solid tumors",

author = "Moser JC and Brendan Curti and comments, {See full list of authors in}",

year = "2023",

month = nov,

day = "1",

language = "Undefined/Unknown",

series = "Articles, Abstracts, and Reports",

type = "Other",

}

TY - GEN

T1 - A phase 1/1b study of the tumor-activated IL-2 prodrug WTX-124 alone or in combination with pembrolizumab in patients with immunotherapy-sensitive locally advanced or metastatic solid tumors

AU - JC, Moser

AU - Curti, Brendan

AU - comments, See full list of authors in

PY - 2023/11/1

Y1 - 2023/11/1

M3 - Other contribution

T3 - Articles, Abstracts, and Reports

ER -